Restoring mitochondrial dysfunction to address neurodegenerative and metabolic diseases

Explore the science

Press release

ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive impairments that are significant enough to interfere with daily life. A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction may contribute to cognitive decline in AD. In this trial, the aim is to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.

Full Press Release

Limitless Possibilities

AI-Driven Scientific Discovery leads to development of pharmaceutical drugs targeting metabolic diseases

Mitochondrial deficiency, characterized by a reduced number of mitochondria or impaired mitochondrial function, is a key factor in many modern health conditions, including neurodegenerative disorders and metabolic syndromes.

Learn More

The Company

What you need to know:

ScandiBio Therapeutics

A Stockholm-based company, is developing a pharmaceutical drugs that targets mitochondrial dysfunction.

Our Lead Product

Has recently entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer’s disease.

We are

Founded by scientists affiliated with KTH Royal Institute Technology (Stockholm), Karolinska Institutet (Stockholm), Sahlgrenska University hospital (Gothenburg) and King´s College (London).